Martin K Angele1, Markus Albertsmeier, Niclas J Prix, Peter Hohenberger, Sultan Abdel-Rahman, Nelli Dieterle, Michael Schmidt, Ulrich Mansmann, Christiane J Bruns, Rolf D Issels, Karl-Walter Jauch, Lars H Lindner. 1. *Department of General, Visceral, Transplantation, Vascular, and Thoracic Surgery and †Department of Internal Medicine III, University of Munich-Campus Grosshadern, Munich, Germany ‡Sarcoma Unit ITM-Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, University of Heidelberg, Mannheim, Germany §Institute of Medical Informatics, Biometry, and Epidemiology, University of Munich-Campus Großhadern, Munich, Germany ¶Department of General, Visceral, and Vascular Surgery, University Hospital Magdeburg, University of Magdeburg, Magdeburg, Germany.
Abstract
OBJECTIVE: To determine whether regional hyperthermia (RHT) in addition to chemotherapy improves local tumor controlafter macroscopically complete resection of abdominal or retroperitoneal high-risk sarcomas. BACKGROUND: Within the prospectively randomized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progression-free survival (LPFS) and disease-free survival (DFS) in patients with abdominal and extremity sarcomas. That trial included macroscopically complete and R2 resections. METHODS: A subgroup analysis of the EORTC trial was performed and long-term survival determined. From 341 patients, 149 (median age 52 years, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G3 51.7%). Seventy-six patients were treated withEIA (etoposide, ifosfamide, doxorubicin)+RHT (≥5 cycles: 69.7%) versus 73 patients receiving EIA alone (≥5 cycles: 52.1%, P=0.027). LPFS and DFS as well as overall survival were determined. RESULTS:RHT and systemic chemotherapy significantly improved LPFS (56% vs 45% after 5 years, P=0.044) and DFS (34% vs 27% after 5 years, P=0.040). Overall survival was not significantly improved in the RHT group (57% vs 55% after 5 years, P=0.82). Perioperative morbidity and mortality were not significantly different between groups. CONCLUSIONS: In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulted in significantly improved local tumor control and DFS without increasing surgical complications. Within a multimodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment option beside radical surgery and should be further evaluated in future trials.
RCT Entities:
OBJECTIVE: To determine whether regional hyperthermia (RHT) in addition to chemotherapy improves local tumor control after macroscopically complete resection of abdominal or retroperitoneal high-risk sarcomas. BACKGROUND: Within the prospectively randomized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progression-free survival (LPFS) and disease-free survival (DFS) in patients with abdominal and extremity sarcomas. That trial included macroscopically complete and R2 resections. METHODS: A subgroup analysis of the EORTC trial was performed and long-term survival determined. From 341 patients, 149 (median age 52 years, 18-69) were identified with macroscopic complete resection (R0, R1) of abdominal and retroperitoneal soft-tissue sarcomas (median diameter 10 cm, G2 48.3%, G3 51.7%). Seventy-six patients were treated with EIA (etoposide, ifosfamide, doxorubicin)+RHT (≥5 cycles: 69.7%) versus 73 patients receiving EIA alone (≥5 cycles: 52.1%, P=0.027). LPFS and DFS as well as overall survival were determined. RESULTS: RHT and systemic chemotherapy significantly improved LPFS (56% vs 45% after 5 years, P=0.044) and DFS (34% vs 27% after 5 years, P=0.040). Overall survival was not significantly improved in the RHT group (57% vs 55% after 5 years, P=0.82). Perioperative morbidity and mortality were not significantly different between groups. CONCLUSIONS: In patients with macroscopically complete tumor resection, RHT in addition to chemotherapy resulted in significantly improved local tumor control and DFS without increasing surgical complications. Within a multimodal therapeutic concept for abdominal and retroperitoneal high-risk sarcomas, RHT is a treatment option beside radical surgery and should be further evaluated in future trials.
Authors: Eduardo A Perez; Juan C Gutierrez; Frederick L Moffat; Dido Franceschi; Alan S Livingstone; Seth A Spector; Joe U Levi; Danny Sleeman; Leonidas G Koniaris Journal: Ann Surg Oncol Date: 2007-01-07 Impact factor: 5.344
Authors: J J Lagendijk; G C Van Rhoon; S N Hornsleth; P Wust; A C De Leeuw; C J Schneider; J D Van Dijk; J Van Der Zee; R Van Heek-Romanowski; S A Rahman; C Gromoll Journal: Int J Hyperthermia Date: 1998 Mar-Apr Impact factor: 3.914
Authors: E Gortzak; A Azzarelli; J Buesa; V H Bramwell; F van Coevorden; A N van Geel; A Ezzat; A Santoro; J W Oosterhuis; M van Glabbeke; A Kirkpatrick; J Verweij Journal: Eur J Cancer Date: 2001-06 Impact factor: 9.162
Authors: C Wendtner; S Abdel-Rahman; J Baumert; M H Falk; M Krych; M Santl; W Hiddemann; R D Issels Journal: Eur J Cancer Date: 2001-09 Impact factor: 9.162
Authors: Juan C Gutierrez; Eduardo A Perez; Dido Franceschi; Frederick L Moffat; Alan S Livingstone; Leonidas G Koniaris Journal: J Surg Res Date: 2007-05-18 Impact factor: 2.192
Authors: Imran Hassan; Saung Z Park; John H Donohue; David M Nagorney; Paul A Kay; Antonio G Nasciemento; Cathy D Schleck; Duane M Ilstrup Journal: Ann Surg Date: 2004-02 Impact factor: 12.969
Authors: David A Mahvi; Rong Liu; Mark W Grinstaff; Yolonda L Colson; Chandrajit P Raut Journal: CA Cancer J Clin Date: 2018-10-17 Impact factor: 508.702
Authors: J Jakob; A Gerres; U Ronellenfitsch; L Pilz; M Wartenberg; B Kasper; H-R Raab; P Hohenberger Journal: Chirurg Date: 2018-01 Impact factor: 0.955
Authors: Oliver Stoetzer; Dorit Di Gioia; Rolf Dieter Issels; Sultan Abdel-Rahman; Ulrich Mansmann; Lars Hartwin Lindner; Oleg Gluz; Rachel Würstlein; Michael Braun; Moritz Hamann; Franz Edler von Koch; Nadia Harbeck; Christoph Salat Journal: Breast Care (Basel) Date: 2020-05-12 Impact factor: 2.860
Authors: Rolf D Issels; Lars H Lindner; Jaap Verweij; Rüdiger Wessalowski; Peter Reichardt; Peter Wust; Pirus Ghadjar; Peter Hohenberger; Martin Angele; Christoph Salat; Zeljko Vujaskovic; Soeren Daugaard; Olav Mella; Ulrich Mansmann; Hans Roland Dürr; Thomas Knösel; Sultan Abdel-Rahman; Michael Schmidt; Wolfgang Hiddemann; Karl-Walter Jauch; Claus Belka; Alessandro Gronchi Journal: JAMA Oncol Date: 2018-04-01 Impact factor: 31.777